Differences in Medication Use in the Alzheimer’s Disease Neuroimaging Initiative

[1]  Joseph V. Hajnal,et al.  A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T) , 2010, NeuroImage.

[2]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[3]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[4]  Nicola Vanacore,et al.  Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials , 2007, PLoS medicine.

[5]  Carmen Fraile,et al.  Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. , 2007, Current Alzheimer research.

[6]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[7]  B. Winblad,et al.  IDEAL , 2007, Neurology.

[8]  J. Schwartz.  The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology , 2007, Clinical pharmacology and therapeutics.

[9]  B. Martin,et al.  Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.

[10]  S. Solomon,et al.  Celecoxib for the prevention of sporadic colorectal adenomas. , 2006, The New England journal of medicine.

[11]  G. Kay,et al.  Antimuscarinic Drugs for Overactive Bladder and Their Potential Effects on Cognitive Function in Older Patients , 2005, Journal of the American Geriatrics Society.

[12]  J. Karlawish,et al.  Would caregivers of Alzheimer disease patients involve their relative in a decision to use an AD-slowing medication? , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[13]  Norbert Schuff,et al.  Measurement of hippocampal subfields and age-related changes with high resolution MRI at 4tesla , 2005, Alzheimer's & Dementia.

[14]  C. Jack,et al.  Ways toward an early diagnosis in Alzheimer’s disease: The Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2005, Alzheimer's & Dementia.

[15]  S. Hulley,et al.  The WHI estrogen-alone trial--do things look any better? , 2004, JAMA.

[16]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[17]  M. Beers,et al.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. , 2003, Archives of internal medicine.

[18]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[19]  B. Gersh,et al.  Amiodarone and mortality among elderly patients with acute myocardial infarction with atrial fibrillation. , 2002, American heart journal.

[20]  C. Dufouil,et al.  Long-Term Benzodiazepine Use and Cognitive Decline in the Elderly: The Epidemiology of Vascular Aging Study , 2002, Journal of clinical psychopharmacology.

[21]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[22]  G. Jensen,et al.  Screening for hospitalization and nutritional risks among community-dwelling older persons. , 2001, The American journal of clinical nutrition.

[23]  J. Karlawish,et al.  How do AD patients and their caregivers decide whether to enroll in a clinical trial? , 2001, Neurology.

[24]  B. Gordon,et al.  Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. , 2001, Archives of neurology.

[25]  H. Perry,et al.  Polypharmacy and hospitalization among older home care patients. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[26]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. González-Montalvo,et al.  Factors predictive of outcome on admission to an acute geriatric ward. , 1999, Age and ageing.

[28]  F. Haaijer-Ruskamp,et al.  Adverse drug reactions and polypharmacy in the elderly in general practice , 1999, European Journal of Clinical Pharmacology.

[29]  T. M. Laughlin.  The ethics of basketball , 1999 .

[30]  A. Dale,et al.  Cortical Surface-Based Analysis II: Inflation, Flattening, and a Surface-Based Coordinate System , 1999, NeuroImage.

[31]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[32]  L. Beilin,et al.  Predictors of medication use, compliance and symptoms of hypotension in a community‐based sample of elderly men and women , 1998, Journal of clinical pharmacy and therapeutics.

[33]  W. Ray,et al.  Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. , 1997, Archives of internal medicine.

[34]  R. Goldberg,et al.  Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. , 1996, The American journal of emergency medicine.

[35]  C. Winograd,et al.  Geriatric Targeting Criteria as Predictors of Survival and Health Care Utilization , 1996, Journal of the American Geriatrics Society.

[36]  L. Nolan,et al.  Prescribing for the Elderly Part I: Sensitivity of the Elderly to Adverse Drug Reactions * , 1988, Journal of the American Geriatrics Society.

[37]  R. Feldman,et al.  AMERICAN ACADEMY OF NEUROLOGY , 1949 .

[38]  P. Lamy.  Prescribing for the elderly , 1980 .